We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Boston Scientific Corporation | NYSE:BSX | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.21 | -0.28% | 74.24 | 74.745 | 74.18 | 74.60 | 1,809,720 | 16:58:06 |
By George Stahl
Boston Scientific Corp. agreed to pay Johnson & Johnson $600 million to settle a long-running lawsuit related to the 2006 acquisition of heart-device maker Guidant Corp. for $27 billion.
J&J had sought more than $7 billion in damages after accusing Guidant of breaching their merger agreement by going with the higher offer from Boston Scientific.
As a result of the settlement announced Tuesday, J&J has agreed to dismiss its lawsuit without acknowledgment of liability by Guidant. Boston Scientific also agreed not to bring patent infringement or other claims related to certain J&J stent products.
Boston Scientific said it would include a charge of $600 million with its fourth-quarter results. On Feb. 4, Boston Scientific reported fourth-quarter earnings of $87 million, or six cents a share, on revenue of $1.89 billion.
In 2006, Boston Scientific made a last-minute bid that snatched away Guidant from J&J.
J&J had worked 18 months to land Guidant, seeking an entree into the big market for devices that regulate errant heart rhythms. J&J had provided an opening for Boston Scientific when it lowered its original offer after Guidant ran into product-quality problems. But when its bid reached $24 billion, few expected upstart Boston Scientific to swoop in with a takeout offer.
While Boston Scientific may have outmaneuvered J&J in the takeover battle, it has struggled since amid a heavy debt load caused by the deal, increased competition in the heart market and the economic downturn last decade.
The company's stock, which was in the mid-$20s in the months leading up to the Guidant deal, has only recently reached $15 after trading several years below it. Shares, though, surged Tuesday following news of the settlement, rising nearly 12% to $16.59 in after-hours trading.
"We view this resolution as a significant positive for [Boston Scientific], lifting what has been a major overhang over the past few months," J.P. Morgan analyst Michael Weinstein said in a note Tuesday.
J&J, meanwhile, trades above $100 after being around $60 in early 2006. Shares of J&J added a penny to $100.45 following the news.
Write to George Stahl at george.stahl@wsj.com
Access Investor Kit for Boston Scientific Corp.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US1011371077
Access Investor Kit for Johnson & Johnson
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US4781601046
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Boston Scientific Chart |
1 Month Boston Scientific Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions